• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Modeling oncogene addiction using RNA interference.利用RNA干扰技术模拟癌基因成瘾
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4. doi: 10.1073/pnas.0803217105. Epub 2008 Aug 18.
2
Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.功能 RNAi 筛选确定了 EGFR 依赖性头颈部鳞状细胞癌细胞系中不同的蛋白激酶缺陷。
Mol Pharmacol. 2019 Dec;96(6):862-870. doi: 10.1124/mol.119.117804. Epub 2019 Sep 25.
3
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.癌基因互换作为肺癌中获得性表皮生长因子受体-酪氨酸激酶抑制剂耐药的一种新机制。
Cancer Sci. 2016 Apr;107(4):461-8. doi: 10.1111/cas.12905. Epub 2016 Mar 28.
4
Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference.通过 RNA 干扰特异性沉默致癌 EGFR 抑制肿瘤细胞。
PLoS One. 2013 Aug 8;8(8):e73214. doi: 10.1371/journal.pone.0073214. eCollection 2013.
5
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.人类激酶组中保守的表皮生长因子受体(EGFR)E884-R958离子对的破坏会不同程度地改变信号传导和抑制剂敏感性。
Oncogene. 2009 Jan 29;28(4):518-33. doi: 10.1038/onc.2008.411. Epub 2008 Nov 17.
6
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.通过磷脂酰肌醇3-激酶(PI3K)/雷帕霉素哺乳动物靶蛋白(mTOR)轴发出的信号负责表皮生长因子受体(EGFR)突变的肺腺癌中由葡萄糖转运蛋白介导的有氧糖酵解。
J Biol Chem. 2015 Jul 10;290(28):17495-504. doi: 10.1074/jbc.M115.660498. Epub 2015 May 28.
7
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.吉非替尼诱导表达突变型表皮生长因子受体(EGFR)的非小细胞肺癌细胞系死亡需要BIM,并且可被BH3模拟物增强。
PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690. doi: 10.1371/journal.pmed.0040316.
8
Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.KRAS siRNA 和 EGFR 抑制剂 AZD8931 的联合治疗抑制肺癌细胞的体外生长。
J Cell Physiol. 2019 Feb;234(2):1560-1566. doi: 10.1002/jcp.27021. Epub 2018 Aug 21.
9
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.致癌性表皮生长因子受体抑制TET1 DNA去甲基化酶以诱导癌细胞中肿瘤抑制基因沉默。
Cell Rep. 2016 Jul 12;16(2):457-471. doi: 10.1016/j.celrep.2016.05.087. Epub 2016 Jun 23.
10
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.BIM介导具有致癌性EGFR突变的肺癌中表皮生长因子受体酪氨酸激酶抑制剂诱导的细胞凋亡。
PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680. doi: 10.1371/journal.pmed.0040315.

引用本文的文献

1
Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.致癌基因突变或过表达的致癌 KRAS 或 BRAF 不足以赋予致癌基因成瘾性。
PLoS One. 2021 Apr 1;16(4):e0249388. doi: 10.1371/journal.pone.0249388. eCollection 2021.
2
Effect of Cetuximab and Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type and Use of as a Possible Biomarker for Treatment Responsiveness.西妥昔单抗与小干扰RNA联合治疗对野生型非小细胞肺癌细胞系的影响以及将其作为治疗反应性可能生物标志物的应用
Yonago Acta Med. 2019 Mar 28;62(1):85-93. doi: 10.33160/yam.2019.03.012. eCollection 2019 Mar.
3
Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants.羧基末端结构域的自动磷酸化对于肺癌衍生的 EGFR 突变体的致癌转化不是必需的。
Int J Cancer. 2018 Aug 1;143(3):679-685. doi: 10.1002/ijc.31332. Epub 2018 Mar 5.
4
Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.SLPI启动子控制的靶向表皮生长因子受体的人工微小RNA在鳞状细胞癌细胞系中的抗肿瘤疗效
Pathol Oncol Res. 2017 Oct;23(4):829-835. doi: 10.1007/s12253-016-0160-8. Epub 2017 Jan 18.
5
Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.组成型不对称二聚化驱动表皮生长因子受体羧基末端缺失突变体的致癌激活。
Oncotarget. 2015 Apr 20;6(11):8839-50. doi: 10.18632/oncotarget.3559.
6
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.肺癌衍生表皮生长因子受体突变体对西妥昔单抗的反应与非对称二聚化有关。
Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.
7
Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.谱系转录因子 GATA6 和 HOPX 通过控制肺泡分化抑制肺腺癌转移。
Cancer Cell. 2013 Jun 10;23(6):725-38. doi: 10.1016/j.ccr.2013.04.009. Epub 2013 May 23.
8
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.阿法替尼与 Su11274 在对吉非替尼或厄洛替尼耐药的非小细胞肺癌细胞中的协同作用。
PLoS One. 2013;8(3):e59708. doi: 10.1371/journal.pone.0059708. Epub 2013 Mar 18.
9
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.MEK 抑制通过解除 ERBB 受体的负反馈而导致 PI3K/AKT 的激活。
Cancer Res. 2012 Jul 1;72(13):3228-37. doi: 10.1158/0008-5472.CAN-11-3747. Epub 2012 May 2.
10
Emerging insights into the molecular and cellular basis of glioblastoma.胶质母细胞瘤的分子和细胞基础的新见解。
Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112.

本文引用的文献

1
Survival of cancer cells is maintained by EGFR independent of its kinase activity.癌细胞的存活由表皮生长因子受体(EGFR)维持,且与其激酶活性无关。
Cancer Cell. 2008 May;13(5):385-93. doi: 10.1016/j.ccr.2008.03.015.
2
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.表皮生长因子受体激酶突变等位基因的致癌活性因T790M耐药突变而增强。
Cancer Res. 2007 Aug 1;67(15):7319-26. doi: 10.1158/0008-5472.CAN-06-4625.
3
Patterns of somatic mutation in human cancer genomes.人类癌症基因组中的体细胞突变模式。
Nature. 2007 Mar 8;446(7132):153-8. doi: 10.1038/nature05610.
4
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.来自人类肺癌的表皮生长因子受体突变体表现出增强的催化活性以及对吉非替尼的敏感性增加。
Cancer Res. 2007 Mar 1;67(5):2325-30. doi: 10.1158/0008-5472.CAN-06-4293.
5
Minimizing the risk of reporting false positives in large-scale RNAi screens.在大规模RNA干扰筛选中最小化报告假阳性的风险。
Nat Methods. 2006 Oct;3(10):777-9. doi: 10.1038/nmeth1006-777.
6
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.表皮生长因子受体体细胞突变蛋白的动力学分析表明,其对表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼的敏感性增加。
Cancer Res. 2006 Aug 15;66(16):8163-71. doi: 10.1158/0008-5472.CAN-06-0453.
7
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.表皮生长因子受体的外显子19缺失突变与接受吉非替尼或厄洛替尼治疗的非小细胞肺癌患者的生存期延长相关。
Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462.
8
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.细胞微小RNA/短发夹RNA通路过度饱和导致小鼠死亡。
Nature. 2006 May 25;441(7092):537-41. doi: 10.1038/nature04791.
9
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.表皮生长因子受体III型变异体突变在肺癌发生及对酪氨酸激酶抑制剂敏感性中的作用
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. doi: 10.1073/pnas.0510284103. Epub 2006 May 3.
10
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.一种用于人类和小鼠基因的慢病毒RNA干扰文库,应用于阵列病毒高内涵筛选。
Cell. 2006 Mar 24;124(6):1283-98. doi: 10.1016/j.cell.2006.01.040.

利用RNA干扰技术模拟癌基因成瘾

Modeling oncogene addiction using RNA interference.

作者信息

Rothenberg S Michael, Engelman Jeffrey A, Le Sheila, Riese David J, Haber Daniel A, Settleman Jeffrey

机构信息

Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.

出版信息

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4. doi: 10.1073/pnas.0803217105. Epub 2008 Aug 18.

DOI:10.1073/pnas.0803217105
PMID:18711136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2517605/
Abstract

The clinical efficacy of selective kinase inhibitors suggests that some cancer cells may become dependent on a single oncogene for survival. RNAi has been increasingly used to understand such "oncogene addiction" and validate new therapeutic targets. However, RNAi approaches suffer from significant off-target effects that limit their utility. Here, we combine carefully titrated lentiviral-mediated short hairpin RNA knockdown of the epidermal growth factor receptor (EGFR) with heterologous reconstitution by EGFR mutants to rigorously analyze the structural features and signaling activities that determine addiction to the mutationally activated EGFR in human lung cancer cells. EGFR dependence is differentially rescued by distinct EGFR variants and oncogenic mutants, is critically dependent on its heterodimerization partner ErbB-3, and surprisingly, does not require autophosphorylation sites in the cytoplasmic domain. Quantitative "oncogene rescue" analysis allows mechanistic dissection of oncogene addiction, and, when broadly applied, may provide functional validation for potential therapeutic targets identified through large-scale RNAi screens.

摘要

选择性激酶抑制剂的临床疗效表明,一些癌细胞可能依赖单一癌基因存活。RNA干扰(RNAi)已越来越多地用于理解这种“癌基因成瘾”并验证新的治疗靶点。然而,RNAi方法存在显著的脱靶效应,限制了其效用。在此,我们将精心滴定的慢病毒介导的表皮生长因子受体(EGFR)短发夹RNA敲低与EGFR突变体的异源重组相结合,以严格分析决定人肺癌细胞对突变激活的EGFR成瘾的结构特征和信号活性。不同的EGFR变体和致癌突变体对EGFR依赖性的挽救存在差异,其关键依赖于其异二聚体伙伴ErbB-3,并且令人惊讶的是,不需要胞质结构域中的自磷酸化位点。定量“癌基因挽救”分析允许对癌基因成瘾进行机制剖析,并且广泛应用时,可能为通过大规模RNAi筛选鉴定的潜在治疗靶点提供功能验证。